title: Data mining experiments on the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF-AFNET 2) trial: 'exposing the invisible'.
abstract: OBJECTIVE
  The aims of this study include (i) pursuing data-mining experiments on the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF-AFNET 2) trial dataset containing atrial fibrillation (AF) burden scores of patients with many clinical parameters and (ii) revealing possible correlations between the estimated risk factors of AF and other clinical findings or measurements provided in the dataset.
  
  
  METHODS
  Ranking Instances by Maximizing the Area under a Receiver Operating Characteristics (ROC) Curve (RIMARC) is used to determine the predictive weights (Pw) of baseline variables on the primary endpoint. Chi-square automatic interaction detector algorithm is performed for comparing the results of RIMARC. The primary endpoint of the ANTIPAF-AFNET 2 trial was the percentage of days with documented episodes of paroxysmal AF or with suspected persistent AF.
  
  
  RESULTS
  By means of the RIMARC analysis algorithm, baseline SF-12 mental component score (Pw= 0.3597), age (Pw= 0.2865), blood urea nitrogen (BUN) (Pw= 0.2719), systolic blood pressure (Pw= 0.2240), and creatinine level (Pw= 0.1570) of the patients were found to be predictors of AF burden. Atrial fibrillation burden increases as baseline SF-12 mental component score gets lower; systolic blood pressure, BUN and creatinine levels become higher; and the patient gets older. The AF burden increased significantly at age >76.
  
  
  CONCLUSIONS
  With the ANTIPAF-AFNET 2 dataset, the present data-mining analyses suggest that a baseline SF-12 mental component score, age, systolic blood pressure, BUN, and creatinine level of the patients are predictors of AF burden. Additional studies are necessary to understand the distinct kidney-specific pathophysiological pathways that contribute to AF burden.
authors.affiliation: Department of Cardiology, Memorial Ankara Hospital, Ankara, Turkey.
authors.forename: Sercan
authors.initials: S
authors.lastname: Okutucu
authors.affiliation: Medical Information Technology Solutions (MITS), Bilkent University Cyberpark, Ankara, Turkey.
authors.forename: Deniz
authors.initials: D
authors.lastname: Katircioglu-Öztürk
authors.affiliation: Medical Information Technology Solutions (MITS), Bilkent University Cyberpark, Ankara, Turkey.
authors.forename: Emre
authors.initials: E
authors.lastname: Oto
authors.affiliation: Department of Computer Engineering, Faculty of Engineering, Bilkent University, Ankara, Turkey.
authors.forename: H Altay
authors.initials: HA
authors.lastname: Güvenir
authors.affiliation: Department of Biostatistics, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
authors.forename: Ergun
authors.initials: E
authors.lastname: Karaagaoglu
authors.affiliation: Department of Cardiology, Memorial Ankara Hospital, Ankara, Turkey.
authors.forename: Ali
authors.initials: A
authors.lastname: Oto
authors.affiliation: Atrial Fibrillation Network Association, Münster, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Meinertz
authors.affiliation: Atrial Fibrillation Network Association, Münster, Germany.|Department of Cardiology, Vincenz-Krankenhaus, Paderborn, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Goette
mesh_terms: D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D057911:Angiotensin Receptor Antagonists / Q000008:administration & dosage*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000453:epidemiology*; D015897:Comorbidity; D057225:Data Mining / Q000379:methods*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000453:epidemiology* / Q000517:prevention & control; D007093:Imidazoles / Q000008:administration & dosage*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012307:Risk Factors; D017678:Sex Distribution; D013777:Tetrazoles / Q000008:administration & dosage*; D016896:Treatment Outcome; D014421:Turkey / Q000453:epidemiology
chemical_list: D057911:Angiotensin Receptor Antagonists; D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D007093:Imidazoles; D013777:Tetrazoles; C437965:olmesartan
keywords: Atrial fibrillation; Blood urea nitrogen; Creatinine; Data mining; Machine learning; RIMARC; SF-12